| Q92965419 | A CRISPR/Cas9 library to map the HIV-1 provirus genetic fitness |
| Q37441674 | A Cas9 Ribonucleoprotein Platform for Functional Genetic Studies of HIV-Host Interactions in Primary Human T Cells |
| Q92378292 | A Practical Guide to Genome Editing Using Targeted Nuclease Technologies |
| Q24635945 | A TALE of two nucleases: gene targeting for the masses? |
| Q37596293 | A cut above the rest: targeted genome editing technologies in human pluripotent stem cells |
| Q36942027 | A genome editing primer for the hematologist |
| Q38201212 | A guide to genome engineering with programmable nucleases |
| Q34589235 | A library of TAL effector nucleases spanning the human genome |
| Q38794948 | A morphospace for synthetic organs and organoids: the possible and the actual |
| Q41959958 | A novel zinc-finger nuclease platform with a sequence-specific cleavage module. |
| Q39180736 | A requirement for wild-type Ras isoforms in mutant KRas-driven signalling and transformation |
| Q35543671 | A systematic survey of the Cys2His2 zinc finger DNA-binding landscape |
| Q35168444 | AAV-mediated delivery of zinc finger nucleases targeting hepatitis B virus inhibits active replication |
| Q39334045 | Adeno-associated virus inverted terminal repeats stimulate gene editing |
| Q38963280 | Adenoviral vector DNA for accurate genome editing with engineered nucleases. |
| Q38028180 | Advances in targeted genome editing |
| Q37680382 | An online bioinformatics tool predicts zinc finger and TALE nuclease off-target cleavage |
| Q37420333 | Analysis of off-target effects of CRISPR/Cas-derived RNA-guided endonucleases and nickases. |
| Q38397580 | Application of CRISPR/Cas9 genome editing to the study and treatment of disease |
| Q47352665 | Applications of Alternative Nucleases in the Age of CRISPR/Cas9. |
| Q91970445 | Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects |
| Q36951105 | Artificial zinc finger DNA binding domains: versatile tools for genome engineering and modulation of gene expression |
| Q36673714 | Assessing the risks of genotoxicity in the therapeutic development of induced pluripotent stem cells |
| Q28069780 | Biased and Unbiased Methods for the Detection of Off-Target Cleavage by CRISPR/Cas9: An Overview |
| Q33586934 | Bioinformatic clonality analysis of next-generation sequencing-derived viral vector integration sites |
| Q58120494 | Blossom of CRISPR technologies and applications in disease treatment |
| Q33566358 | Broad specificity profiling of TALENs results in engineered nucleases with improved DNA-cleavage specificity |
| Q29615783 | CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering |
| Q41721624 | CCR5 Gene Editing of Resting CD4(+) T Cells by Transient ZFN Expression From HIV Envelope Pseudotyped Nonintegrating Lentivirus Confers HIV-1 Resistance in Humanized Mice |
| Q39197846 | CD34+ hematopoietic stem cells support entry and replication of poliovirus: a potential new gene introduction route |
| Q48213026 | CIRCLE-seq: a highly sensitive in vitro screen for genome-wide CRISPR-Cas9 nuclease off-targets |
| Q88627116 | CRISPR GENOME SURGERY IN THE RETINA IN LIGHT OF OFF-TARGETING |
| Q45864903 | CRISPR technology for gene therapy |
| Q55383943 | CRISPR therapeutic tools for complex genetic disorders and cancer (Review). |
| Q42391311 | CRISPR/Cas9 Targeted Gene Editing and Cellular Engineering in Fanconi Anemia. |
| Q38202388 | CRISPR/Cas9 and TALEN-mediated knock-in approaches in zebrafish |
| Q37271186 | CRISPR/Cas9 systems targeting β-globin and CCR5 genes have substantial off-target activity |
| Q38758476 | CRISPR/Cas9-Mediated Correction of the Sickle Mutation in Human CD34+ cells |
| Q39185865 | CRISPR/Cas9-mediated genome editing in plants |
| Q104495357 | CRISPR/Cas9-mediated knock-in of alligator cathelicidin gene in a non-coding region of channel catfish genome |
| Q48114494 | Chemical Approach to Biological Safety: Molecular-Level Control of an Integrated Zinc Finger Nuclease. |
| Q36144775 | Chimeric piggyBac transposases for genomic targeting in human cells |
| Q28083608 | Chromatin regulation at the frontier of synthetic biology |
| Q38765066 | Combining Single Strand Oligodeoxynucleotides and CRISPR/Cas9 to Correct Gene Mutations in β-Thalassemia-induced Pluripotent Stem Cells |
| Q40383923 | Compact designer TALENs for efficient genome engineering |
| Q42177324 | Computational and molecular tools for scalable rAAV-mediated genome editing. |
| Q42235631 | Construction and characterization of adenoviral vectors for the delivery of TALENs into human cells. |
| Q34381076 | Controlling gene networks and cell fate with precision-targeted DNA-binding proteins and small-molecule-based genome readers |
| Q43149657 | Controversies in HIV cure research |
| Q35153108 | Correction of dystrophin expression in cells from Duchenne muscular dystrophy patients through genomic excision of exon 51 by zinc finger nucleases |
| Q35533589 | Correction of the sickle cell disease mutation in human hematopoietic stem/progenitor cells |
| Q38682882 | Creating and evaluating accurate CRISPR-Cas9 scalpels for genomic surgery |
| Q40396022 | Creating highly specific nucleases by fusion of active restriction endonucleases and catalytically inactive homing endonucleases. |
| Q29393523 | Current progress and challenges in HIV gene therapy |
| Q64071396 | Cut-and-Run: A Distinct Mechanism by which V(D)J Recombination Causes Genome Instability |
| Q35613598 | Cytotoxic Effects during Knock Out of Multiple Porcine Endogenous Retrovirus (PERV) Sequences in the Pig Genome by Zinc Finger Nucleases (ZFN). |
| Q51603184 | DNA Breaks and End Resection Measured Genome-wide by End Sequencing. |
| Q58606914 | DNA methylation and de-methylation using hybrid site-targeting proteins |
| Q57810989 | Defining CRISPR-Cas9 genome-wide nuclease activities with CIRCLE-seq |
| Q38810667 | Defining and improving the genome-wide specificities of CRISPR-Cas9 nucleases |
| Q56610090 | Delivering CRISPR: a review of the challenges and approaches |
| Q39197557 | Delivery technologies for genome editing |
| Q26787105 | Designed nucleases for targeted genome editing |
| Q35975147 | Detecting DNA double-stranded breaks in mammalian genomes by linear amplification-mediated high-throughput genome-wide translocation sequencing |
| Q35422003 | Determining the specificities of TALENs, Cas9, and other genome-editing enzymes |
| Q28241526 | Development and applications of CRISPR-Cas9 for genome engineering |
| Q38911544 | Digenome-seq: genome-wide profiling of CRISPR-Cas9 off-target effects in human cells |
| Q39979692 | Directed evolution of a recombinase that excises the provirus of most HIV-1 primary isolates with high specificity. |
| Q38897833 | Directed evolution of λ integrase activity and specificity by genetic derepression |
| Q57020648 | Dissecting Tissue-Specific Super-Enhancers by Integrating Genome-Wide Analyses and CRISPR/Cas9 Genome Editing |
| Q38034966 | Dissecting neural function using targeted genome engineering technologies. |
| Q36491274 | EENdb: a database and knowledge base of ZFNs and TALENs for endonuclease engineering |
| Q52431143 | Efficient In Vivo Liver-Directed Gene Editing Using CRISPR/Cas9 |
| Q34325074 | Efficient clinical scale gene modification via zinc finger nuclease-targeted disruption of the HIV co-receptor CCR5 |
| Q43180292 | Efficient correction of hemoglobinopathy-causing mutations by homologous recombination in integration-free patient iPSCs |
| Q50496238 | Efficient targeted mutagenesis of the chordate Ciona intestinalis genome with zinc-finger nucleases. |
| Q26782747 | Enabling functional genomics with genome engineering |
| Q60955054 | Endogenous DNA Double-Strand Breaks during DNA Transactions: Emerging Insights and Methods for Genome-Wide Profiling |
| Q26785927 | Engineered Viruses as Genome Editing Devices |
| Q34257442 | Engineered zinc finger nickases induce homology-directed repair with reduced mutagenic effects |
| Q28086801 | Engineering T Cells to Functionally Cure HIV-1 Infection |
| Q55359800 | Engineering altered protein-DNA recognition specificity. |
| Q37701711 | Enhancing the specificity of recombinase-mediated genome engineering through dimer interface redesign. |
| Q36675286 | Evaluation of TCR Gene Editing Achieved by TALENs, CRISPR/Cas9, and megaTAL Nucleases |
| Q48529117 | Ex vivo and in vivo genome editing: a regulatory scientific framework from early development to clinical implementation |
| Q98164401 | Ex vivo editing of human hematopoietic stem cells for erythroid expression of therapeutic proteins |
| Q41290633 | Exome sequencing in the knockin mice generated using the CRISPR/Cas system |
| Q38255828 | Expanding the genetic editing tool kit: ZFNs, TALENs, and CRISPR-Cas9. |
| Q26995224 | Expanding the scope of site-specific recombinases for genetic and metabolic engineering |
| Q37701251 | Expanding the zinc-finger recombinase repertoire: directed evolution and mutational analysis of serine recombinase specificity determinants. |
| Q36573684 | FLASH assembly of TALENs for high-throughput genome editing |
| Q35077625 | Fanconi anemia gene editing by the CRISPR/Cas9 system |
| Q36922762 | Find and replace: editing human genome in pluripotent stem cells |
| Q26781859 | From Gene Targeting to Genome Editing: Transgenic animals applications and beyond |
| Q98471385 | GOTI, a method to identify genome-wide off-target effects of genome editing in mouse embryos |
| Q34136933 | GT-Scan: identifying unique genomic targets |
| Q34454104 | GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases |
| Q46398292 | Gene Editing and Human Pluripotent Stem Cells: Tools for Advancing Diabetes Disease Modeling and Beta-Cell Development |
| Q38916142 | Gene Editing of Human Hematopoietic Stem and Progenitor Cells: Promise and Potential Hurdles. |
| Q38852141 | Gene correction in patient-specific iPSCs for therapy development and disease modeling |
| Q38846192 | Gene editing and its application for hematological diseases |
| Q36326838 | Gene editing toward the use of autologous therapies in recessive dystrophic epidermolysis bullosa |
| Q90383791 | Gene therapy and genome editing for primary immunodeficiency diseases |
| Q27007012 | Gene therapy on the move |
| Q38607706 | Gene therapy returns to centre stage |
| Q37673157 | Gene therapy targeting HIV entry |
| Q34599142 | Gene- and protein-delivered zinc finger-staphylococcal nuclease hybrid for inhibition of DNA replication of human papillomavirus |
| Q36590372 | Generation and genetic engineering of human induced pluripotent stem cells using designed zinc finger nucleases |
| Q35184193 | Generation of X-CGD cells for vector evaluation from healthy donor CD34(+) HSCs by shRNA-mediated knock down of gp91(phox). |
| Q38170509 | Genetic correction using engineered nucleases for gene therapy applications |
| Q36596865 | Genetic treatment of a molecular disorder: gene therapy approaches to sickle cell disease |
| Q92663423 | Genome Editing for Mucopolysaccharidoses |
| Q26752488 | Genome Engineering with TALE and CRISPR Systems in Neuroscience |
| Q34529971 | Genome editing and the next generation of antiviral therapy. |
| Q38113338 | Genome editing of human pluripotent stem cells to generate human cellular disease models |
| Q35612053 | Genome editing strategies: potential tools for eradicating HIV-1/AIDS. |
| Q47392998 | Genome editing technologies to fight infectious diseases |
| Q41711054 | Genome editing: a tool for research and therapy: targeted genome editing hits the clinic |
| Q38842828 | Genome engineering tools for building cellular models of disease |
| Q39026438 | Genome-Editing Technologies: Principles and Applications |
| Q26769662 | Genome-editing Technologies for Gene and Cell Therapy |
| Q47590940 | Genome-wide Mapping of Off-Target Events in Single-Stranded Oligodeoxynucleotide-Mediated Gene Repair Experiments |
| Q37717900 | Genome-wide Specificity of Highly Efficient TALENs and CRISPR/Cas9 for T Cell Receptor Modification |
| Q101166878 | Genome-wide detection of DNA double-strand breaks by in-suspension BLISS |
| Q35060760 | Genome-wide detection of DNA double-stranded breaks induced by engineered nucleases. |
| Q38842681 | Genome-wide target specificities of CRISPR RNA-guided programmable deaminases |
| Q45938620 | Genomes in Focus: Development and Applications of CRISPR-Cas9 Imaging Technologies. |
| Q36915157 | Genomic editing of the HIV-1 coreceptor CCR5 in adult hematopoietic stem and progenitor cells using zinc finger nucleases |
| Q38186557 | HIV/AIDS: modified stem cells in the spotlight |
| Q27001570 | Hematopoietic stem cell engineering at a crossroads |
| Q27023434 | Hematopoietic-stem-cell-based gene therapy for HIV disease |
| Q33698508 | High-efficiency genome editing via 2A-coupled co-expression of fluorescent proteins and zinc finger nucleases or CRISPR/Cas9 nickase pairs |
| Q29616045 | High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells |
| Q33657682 | Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins |
| Q36228544 | Highly efficient generation of heritable zebrafish gene mutations using homo- and heterodimeric TALENs |
| Q38530599 | Highly efficient homology-driven genome editing in human T cells by combining zinc-finger nuclease mRNA and AAV6 donor delivery. |
| Q21090483 | Highly significant antiviral activity of HIV-1 LTR-specific tre-recombinase in humanized mice |
| Q37406920 | Histone deacetylase inhibition rescues gene knockout levels achieved with integrase-defective lentiviral vectors encoding zinc-finger nucleases. |
| Q37974988 | Homologous recombination-based gene therapy for the primary immunodeficiencies |
| Q36828138 | Homology-driven genome editing in hematopoietic stem and progenitor cells using ZFN mRNA and AAV6 donors. |
| Q26777801 | How specific is CRISPR/Cas9 really? |
| Q90402550 | ITR-Seq, a next-generation sequencing assay, identifies genome-wide DNA editing sites in vivo following adeno-associated viral vector-mediated genome editing |
| Q35161372 | Improved cell-penetrating zinc-finger nuclease proteins for precision genome engineering |
| Q37236800 | In silico abstraction of zinc finger nuclease cleavage profiles reveals an expanded landscape of off-target sites |
| Q58054245 | In vitro-transcribed guide RNAs trigger an innate immune response via the RIG-I pathway |
| Q35653800 | Increased Specific Labeling of INS-1 Pancreatic Beta-Cell by Using RIP-Driven Cre Mutants with Reduced Activity |
| Q34525438 | Induced Pluripotent Stem Cells Meet Genome Editing |
| Q35241569 | Integration of drug, protein, and gene delivery systems with regenerative medicine |
| Q51584789 | Interfacing synthetic DNA logic operations with protein outputs. |
| Q41936505 | Inverted terminal repeats of adeno-associated virus decrease random integration of a gene targeting fragment in Saccharomyces cerevisiae. |
| Q84859556 | Keeping ZFNs on target |
| Q35745432 | Lentivector Knockdown of CCR5 in Hematopoietic Stem and Progenitor Cells Confers Functional and Persistent HIV-1 Resistance in Humanized Mice |
| Q42213094 | Lentiviral protein delivery of meganucleases in human cells mediates gene targeting and alleviates toxicity |
| Q34385265 | Linear amplification mediated PCR--localization of genetic elements and characterization of unknown flanking DNA. |
| Q33715367 | Long-Term Assessment of AAV-Mediated Zinc Finger Nuclease Expression in the Mouse Brain. |
| Q92689026 | Low dose ionizing radiation strongly stimulates insertional mutagenesis in a γH2AX dependent manner |
| Q27010108 | Making designer mutants in model organisms |
| Q52423390 | Mapping the precision of genome editing. |
| Q39126523 | May I Cut in? Gene Editing Approaches in Human Induced Pluripotent Stem Cells |
| Q27011906 | Measuring and Reducing Off-Target Activities of Programmable Nucleases Including CRISPR-Cas9 |
| Q42726265 | MegaTevs: single-chain dual nucleases for efficient gene disruption |
| Q26778992 | Minimizing off-Target Mutagenesis Risks Caused by Programmable Nucleases |
| Q36945218 | Minireview: Genome Editing of Human Pluripotent Stem Cells for Modeling Metabolic Disease. |
| Q90549130 | Mitigating off-target effects in CRISPR/Cas9-mediated in vivo gene editing |
| Q37979243 | Molecular scissors for in situ cellular repair |
| Q35887393 | Multi-reporter selection for the design of active and more specific zinc-finger nucleases for genome editing |
| Q36675323 | Multidimensional Genome-wide Analyses Show Accurate FVIII Integration by ZFN in Primary Human Cells |
| Q88540277 | Myoediting: Toward Prevention of Muscular Dystrophy by Therapeutic Genome Editing |
| Q24631042 | Newer gene editing technologies toward HIV gene therapy |
| Q38519892 | Novel Genome-Editing Tools to Model and Correct Primary Immunodeficiencies. |
| Q26770012 | Nuclease Target Site Selection for Maximizing On-target Activity and Minimizing Off-target Effects in Genome Editing |
| Q39244770 | Obligate ligation-gated recombination (ObLiGaRe): custom-designed nuclease-mediated targeted integration through nonhomologous end joining |
| Q26859390 | Off-target Effects in CRISPR/Cas9-mediated Genome Engineering |
| Q38840666 | Off-target effects of engineered nucleases |
| Q84859398 | On target? Tracing zinc-finger-nuclease specificity |
| Q26778501 | Origins of Programmable Nucleases for Genome Engineering |
| Q48152553 | Partial DNA-guided Cas9 enables genome editing with reduced off-target activity. |
| Q37661804 | Passenger mutations and aberrant gene expression in congenic tissue plasminogen activator-deficient mouse strains |
| Q28541724 | Precise gene modification mediated by TALEN and single-stranded oligodeoxynucleotides in human cells |
| Q24611750 | Precision editing of large animal genomes |
| Q64989716 | Precision gene editing technology and applications in nephrology. |
| Q38214809 | Precision genome editing: a small revolution for glycobiology. |
| Q36093894 | Precision genome engineering with programmable DNA-nicking enzymes |
| Q37403787 | Preclinical development and qualification of ZFN-mediated CCR5 disruption in human hematopoietic stem/progenitor cells |
| Q38761853 | Programmable Site-Specific Nucleases for Targeted Genome Engineering in Higher Eukaryotes |
| Q36907411 | Progress and prospects in stem cell therapy |
| Q38618624 | Proteomics in the genome engineering era. |
| Q33587979 | Quantifying genome-editing outcomes at endogenous loci with SMRT sequencing |
| Q27015049 | Quantifying on- and off-target genome editing |
| Q44457276 | RNA guides genome engineering |
| Q49196789 | RNA-Seq Analysis of an Antisense Sequence Optimized for Exon Skipping in Duchenne Patients Reveals No Off-Target Effect. |
| Q34025414 | RNA-directed gene editing specifically eradicates latent and prevents new HIV-1 infection. |
| Q39457863 | RNAi-Mediated CCR5 Knockdown Provides HIV-1 Resistance to Memory T Cells in Humanized BLT Mice |
| Q50281015 | Re-engineered RNA-Guided FokI-Nucleases for Improved Genome Editing in Human Cells. |
| Q41093129 | Reactivating Fetal Hemoglobin Expression in Human Adult Erythroblasts Through BCL11A Knockdown Using Targeted Endonucleases |
| Q38025056 | Recent advances in targeted genome engineering in mammalian systems |
| Q27013114 | Recent developments in human immunodeficiency virus-1 latency research |
| Q30545902 | Recombinant probes for visualizing endogenous synaptic proteins in living neurons |
| Q37659896 | Redesign of extensive protein-DNA interfaces of meganucleases using iterative cycles of in vitro compartmentalization |
| Q35790419 | Redesigning Recombinase Specificity for Safe Harbor Sites in the Human Genome |
| Q34286622 | Reducing ligation bias of small RNAs in libraries for next generation sequencing |
| Q50097987 | Reprint of: Virus-Specific T Cells: Broadening Applicability |
| Q35637089 | Rescue of DNA-PK Signaling and T-Cell Differentiation by Targeted Genome Editing in a prkdc Deficient iPSC Disease Model. |
| Q26991660 | Retroviral integrations in gene therapy trials |
| Q37291607 | Robust ZFN-mediated genome editing in adult hemophilic mice. |
| Q38706622 | Salient Features of Endonuclease Platforms for Therapeutic Genome Editing |
| Q42784808 | Sculpting genomes with a hammer and chisel |
| Q48925635 | Seamless genome editing in human pluripotent stem cells using custom endonuclease-based gene targeting and the piggyBac transposon |
| Q34110518 | Selection-independent generation of gene knockout mouse embryonic stem cells using zinc-finger nucleases |
| Q26781370 | Single-Base Pair Genome Editing in Human Cells by Using Site-Specific Endonucleases |
| Q39875872 | Site- and strand-specific nicking of DNA by fusion proteins derived from MutH and I-SceI or TALE repeats |
| Q59360193 | Site-Specific Gene Editing of Human Hematopoietic Stem Cells for X-Linked Hyper-IgM Syndrome |
| Q38314119 | Stem cell gene therapy for HIV: strategies to inhibit viral entry and replication |
| Q37458718 | Successful correction of hemophilia by CRISPR/Cas9 genome editing in vivo: delivery vector and immune responses are the key to success. |
| Q33863533 | Succession of transiently active tumor-initiating cell clones in human pancreatic cancer xenografts |
| Q38856090 | T-cell therapies for HIV: Preclinical successes and current clinical strategies. |
| Q35070354 | TALE-PvuII fusion proteins--novel tools for gene targeting. |
| Q36915141 | TALEN-based gene correction for epidermolysis bullosa. |
| Q42228950 | TALEN-mediated editing of endogenous T-cell receptors facilitates efficient reprogramming of T lymphocytes by lentiviral gene transfer |
| Q33702173 | TALEN-mediated genetic tailoring as a tool to analyze the function of acquired mutations in multiple myeloma cells |
| Q37543719 | TALEN-mediated single-base-pair editing identification of an intergenic mutation upstream of BUB1B as causative of PCS (MVA) syndrome. |
| Q33698693 | TALENs facilitate targeted genome editing in human cells with high specificity and low cytotoxicity |
| Q35114320 | Target specificity of the CRISPR-Cas9 system. |
| Q34475751 | Targeted DNA excision in Arabidopsis by a re-engineered homing endonuclease |
| Q41844091 | Targeted Gene Addition of Microdystrophin in Mice Skeletal Muscle via Human Myoblast Transplantation |
| Q35791576 | Targeted chromosomal duplications and inversions in the human genome using zinc finger nucleases |
| Q36777548 | Targeted gene addition in human CD34(+) hematopoietic cells for correction of X-linked chronic granulomatous disease |
| Q34088395 | Targeted gene correction minimally impacts whole-genome mutational load in human-disease-specific induced pluripotent stem cell clones. |
| Q42595840 | Targeted gene editing by transfection of in vitro reconstituted Streptococcus thermophilus Cas9 nuclease complex |
| Q36179350 | Targeted gene knockout by direct delivery of zinc-finger nuclease proteins |
| Q38005211 | Targeted gene therapies: tools, applications, optimization |
| Q41822307 | Targeted genome editing in human repopulating haematopoietic stem cells |
| Q57809338 | Targeted integration in human cells through single crossover mediated by ZFN or CRISPR/Cas9 |
| Q34299854 | Targeted integration of a rAAV vector into the AAVS1 region |
| Q47417619 | Targeted mutagenesis: A sniper-like diversity generator in microbial engineering |
| Q24599859 | Targeting DNA With Fingers and TALENs |
| Q36405378 | Targeting wild-type Erythrocyte receptors for Plasmodium falciparum and vivax Merozoites by Zinc Finger Nucleases In- silico: Towards a Genetic Vaccine against Malaria |
| Q33784986 | The I-TevI nuclease and linker domains contribute to the specificity of monomeric TALENs |
| Q38896928 | The genome editing revolution: A CRISPR-Cas TALE off-target story. |
| Q27691999 | The tandem β-zipper: modular binding of tandem domains and linear motifs. |
| Q28087380 | Therapeutic genome editing: prospects and challenges |
| Q104111445 | Tools for experimental and computational analyses of off-target editing by programmable nucleases |
| Q26773287 | Towards a new era in medicine: therapeutic genome editing |
| Q37236764 | Transcription activator like effector (TALE)-directed piggyBac transposition in human cells |
| Q36876725 | Transcriptional repression of Gata3 is essential for early B cell commitment. |
| Q57493531 | Transient Retrovirus-Based CRISPR/Cas9 All-in-One Particles for Efficient, Targeted Gene Knockout |
| Q33843093 | Type II restriction endonucleases--a historical perspective and more |
| Q42174678 | Unbiased detection of off-target cleavage by CRISPR-Cas9 and TALENs using integrase-defective lentiviral vectors. |
| Q99561776 | Unbiased investigation of specificities of prime editing systems in human cells |
| Q55546604 | VSV-G-Enveloped Vesicles for Traceless Delivery of CRISPR-Cas9. |
| Q33782783 | Vector integration and tumorigenesis |
| Q35823895 | Versatile and efficient genome editing in human cells by combining zinc-finger nucleases with adeno-associated viral vectors. |
| Q45326335 | Virus-Specific T Cells: Broadening Applicability |
| Q47279794 | Xenotransplantation: back to the future? |
| Q29615505 | ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering |
| Q39216030 | Zinc Finger Nuclease induced DNA double stranded breaks and rearrangements in MLL. |
| Q37241457 | Zinc Finger Nucleases: Tailor-made for Gene Therapy |
| Q36437222 | Zinc finger arrays binding human papillomavirus types 16 and 18 genomic DNA: precursors of gene-therapeutics for in-situ reversal of associated cervical neoplasia |
| Q34058383 | Zinc finger endonuclease targeting PSIP1 inhibits HIV-1 integration |
| Q31120020 | Zinc finger nuclease mediated knockout of ADP-dependent glucokinase in cancer cell lines: effects on cell survival and mitochondrial oxidative metabolism |
| Q34268053 | Zinc finger nucleases for targeted mutagenesis and repair of the sickle-cell disease mutation: An in-silico study |
| Q37982615 | Zinc finger nucleases: looking toward translation. |
| Q85075335 | Zinc fingers hit off target |
| Q36528994 | Zinc-finger nuclease-mediated correction of α-thalassemia in iPS cells |
| Q36079444 | Zinc-finger nuclease-mediated targeted insertion of reporter genes for quantitative imaging of gene expression in sea urchin embryos. |
| Q34113366 | Zinc-finger nucleases: how to play two good hands |
| Q61446907 | iGUIDE: an improved pipeline for analyzing CRISPR cleavage specificity |
| Q35770689 | mRNA transfection of a novel TAL effector nuclease (TALEN) facilitates efficient knockout of HIV co-receptor CCR5. |
| Q30572833 | megaTALs: a rare-cleaving nuclease architecture for therapeutic genome engineering |
| Q41124443 | rDNA-directed integration by an HIV-1 integrase--I-PpoI fusion protein |